LB Pharmaceuticals Inc

What they do

The company is developing LB-102, a methylated derivative of amisulpride, which is approved in over 50 countries but not in the United States. LB-102 is in a pivotal Phase 3 trial (NOVA-2) for acute schizophrenia, a 52-week open-label safety trial (NOVA-3), a Phase 2 trial (ILLUMINATE-1) for bipolar 1 depression, and a planned Phase 2 trial in adjunctive major depressive disorder. It is also developing a long-acting injectable formulation and has stated plans to expand LB-102 into new indications. The company does not report product revenue.

Revenue drivers

• LB-102 (pre-revenue, clinical stage) — No product revenue is reported; the company's filings describe LB-102 as its lead asset with a market opportunity cited as the approximately $12 billion U.S. branded antipsychotic market as of 2025.
• Schizophrenia indication (NOVA-2 / NOVA-3) — The pivotal Phase 3 NOVA-2 trial in acute schizophrenia is the most advanced program and the gateway to a pre-NDA meeting and potential NDA submission.
• Mood disorder indications — Phase 2 ILLUMINATE-1 in bipolar 1 depression is enrolling with topline data expected in Q1 2028; a Phase 2 in adjunctive MDD is planned for early 2027 with data expected in the first half of 2029.

Recent performance

R&D expenses were $44.1 million for Q2 2026, up $41.7 million from $2.4 million in Q2 2025, driven by the Phase 3 schizophrenia trial. The company reported cash, cash equivalents, and marketable securities of $327.8 million as of June 30, 2026. Balance-sheet data as of June 30, 2026 show total assets of $361.7 million, total liabilities of $29.3 million, and shareholder equity of $332.3 million. For full-year 2025, net loss was $25.2 million, improving from a $63.1 million net loss in 2024, and operating cash use was $35.2 million in 2025 versus $53.1 million in 2024.

Strategy

Management's stated priority is executing the pivotal Phase 3 NOVA-2 trial in schizophrenia and preparing a pre-NDA meeting with the FDA in the second half of 2027. The company raised a $150.0 million private placement in July 2026 with new and existing institutional investors, intended to fund expansion of LB-102 into new indications, potentially including negative symptoms of schizophrenia and Alzheimer's disease psychosis/agitation, plus general corporate purposes. It expects the proceeds, combined with existing cash, to fund operations beyond Q2 2029 and through multiple clinical milestones. It also plans a Phase 2 adjunctive MDD trial and is developing a long-acting injectable formulation.

Risks

• No approved product or revenue — LB-102 is unapproved and the company has no product revenue, so value depends entirely on clinical and regulatory success.
• Clinical trial timing and outcomes — Topline NOVA-2 data moved forward to the first half of 2027 based on enrollment pace, but trial results may not support approval.
• Regulatory approval uncertainty — LB-102 requires an NDA submission and FDA review, with a pre-NDA meeting planned for the second half of 2027.
• Dependence on third-party manufacturers and service providers — The 10-K risk factors cite reliance on third-party suppliers and manufacturers and their ability to scale production and product yield.

Outlook

Management projects topline data from the pivotal Phase 3 NOVA-2 trial in schizophrenia in the first half of 2027 and a pre-NDA meeting with the FDA in the second half of 2027. It expects topline data from the Phase 2 ILLUMINATE-1 trial in bipolar depression in the first quarter of 2028 and from the Phase 2 trial in adjunctive MDD in the first half of 2029. A Phase 2 MDD trial is expected to start in early 2027, and the company says its cash position should fund operations beyond Q2 2029.